October 5, 2021
Bayer to invest over €400 million to increase access to modern contraception
Bayer announced to invest over €400 million, reinforcing its commitment to providing 100 million women and girls with access to…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
October 5, 2021
Merck to seek emergency use authorization for Molnupiravir, oral antiviral medicine for COVID-19
The drug maker Merck said it plans to seek emergency use authorization in the U.S. as soon as possible and to submit applications to regulatory agencies worldwide for Molnupiravir, which could be the first oral antiviral medicine for COVID-19.
September 30, 2021
Novartis data show rapid and effective disease activity control with remibrutinib in patients with chronic spontaneous urticaria
Novartis today announced positive Phase IIb data showing remibrutinib (LOU064), a potentially best-in-class oral BTK inhibitor, demonstrated rapid and effective disease control in patients with inadequately controlled chronic spontaneous urticaria (CSU).
September 30, 2021
LEO Pharma shared new Adtralza results
LEO Pharma shared results showing that after two years of continuous treatment with Adtralza, adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference
September 29, 2021
Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life
Novartis’ dana from new analysis from a Phase IIb study has showed the importance of achieving complete control of chronic spontaneous urticaria (CSU) symptoms in improving overall health-related quality of life (HRQoL) for patients, as complete control of symptoms brings enormous benefit to people with CSU and is associated with improvements in key HRQoL measures such as overall quality of life, sleep interference, activity interference and work impairment.
September 20, 2021
Cellbox Solutions kicks off subsidiary in the USA
Cellbox Solutions GmbH, developer of the patented Cellbox technology, has founded their U.S. company and is now selling products directly to the U.S./North American market.
September 20, 2021
Santhera nets CHF 45 Million in funding
Santhera Pharmaceuticals has announced a cahs boost with an oversubscribed equity financing of CHF 20 million, a placement of private convertible bonds of CHF 15 million and upsizing of an existing financing arrangement of up to CHF 10 million.
September 20, 2021
Oncimmune to evaluate autoantibody profiles
Oncimmune Holdings has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases.
September 20, 2021
Novartis, Harmonia move to Phase III trial to test Kisqali vs. Ibrance in patients with advanced breast cancer
Novartis said Monday it has started a collaboration with SOLTI Innovative Cancer Research (SOLTI) on HARMONIA, an international, randomized, Phase III, multicenter, open-label study of Kisqali (ribociclib) versus Ibrance (palbociclib),.
September 13, 2021
MGC Pharmaceuticals granted UK Import permit for CannEpil+
CannEpil+ , based on CannEpil, designed by MGC Pharma to treat Refractory Epilepsy, has been approved for import into the UK by the Medicines and Healthcare products Regulatory Agency via its UK distribution and clinical access partner Elite Pharmaco.